Announcements Trials

Browse Landscape

Status

No longer available 1

Sponsor Class

Study Type

Interventional 48 Observational 3 Expanded_access 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Hodgkin Disease 1

Interventions

venetoclax 3 fludarabine phosphate 3 fludarabine 3 navitoclax 2 ibrutinib 2 brexucabtagene autoleucel 2 axicabtagene ciloleucel 2 asparaginase erwinia chrysanthemi recombinant 2 Cyclophosphamide 2 zanubrutinib 1 tisagenlecleucel 1 tipifarnib 1 tafasitamab 1 sugemalimab 1 selinexor 1 plerixafor 1 pirtobrutinib 1 nilotinib 1 midostaurin 1 loncastuximab tesirine 1 idelalisib 1 glucarpidase 1 eryaspase 1 ceritinib 1 Whole-Body Irradiation 1 Tacrolimus 1 Rituximab 1 Proton Pump Inhibitors 1 Mycophenolic Acid 1 Hydrocortisone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × plerixafor × Lymphoid × Clear all

NCT00720603 2015-03-24

EAP

Sanofi

No longer available

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡